Last reviewed · How we verify
CN commercial Dupixent®
CN commercial Dupixent® is a Small molecule drug developed by Jiangsu Genscend Biopharmaceutical Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | CN commercial Dupixent® |
|---|---|
| Sponsor | Jiangsu Genscend Biopharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CN commercial Dupixent® CI brief — competitive landscape report
- CN commercial Dupixent® updates RSS · CI watch RSS
- Jiangsu Genscend Biopharmaceutical Co., Ltd portfolio CI
Frequently asked questions about CN commercial Dupixent®
What is CN commercial Dupixent®?
CN commercial Dupixent® is a Small molecule drug developed by Jiangsu Genscend Biopharmaceutical Co., Ltd.
Who makes CN commercial Dupixent®?
CN commercial Dupixent® is developed by Jiangsu Genscend Biopharmaceutical Co., Ltd (see full Jiangsu Genscend Biopharmaceutical Co., Ltd pipeline at /company/jiangsu-genscend-biopharmaceutical-co-ltd).
What development phase is CN commercial Dupixent® in?
CN commercial Dupixent® is in Phase 1.